Frontiers in Cell and Developmental Biology (Sep 2021)
Mitochondrial Breast Cancer Resistant Protein Sustains the Proliferation and Survival of Drug-Resistant Breast Cancer Cells by Regulating Intracellular Reactive Oxygen Species
- He Zhang,
- He Zhang,
- He Zhang,
- He Zhang,
- Xingxing Han,
- Xingxing Han,
- Xingxing Han,
- Xingxing Han,
- Zhaosong Wang,
- Zhaosong Wang,
- Zhaosong Wang,
- Zhaosong Wang,
- Zhiyong Wang,
- Zhiyong Wang,
- Zhiyong Wang,
- Zhiyong Wang,
- Yanfen Cui,
- Yanfen Cui,
- Yanfen Cui,
- Yanfen Cui,
- Ran Tian,
- Ran Tian,
- Ran Tian,
- Ran Tian,
- Yuying Zhu,
- Yuying Zhu,
- Yuying Zhu,
- Yuying Zhu,
- Baoai Han,
- Baoai Han,
- Baoai Han,
- Baoai Han,
- Hui Liu,
- Hui Liu,
- Hui Liu,
- Hui Liu,
- Xiaoyan Zuo,
- Xiaoyan Zuo,
- Xiaoyan Zuo,
- Xiaoyan Zuo,
- Sixin Ren,
- Sixin Ren,
- Sixin Ren,
- Sixin Ren,
- Jianfei Tian,
- Jianfei Tian,
- Jianfei Tian,
- Jianfei Tian,
- Ruifang Niu,
- Ruifang Niu,
- Ruifang Niu,
- Ruifang Niu,
- Fei Zhang,
- Fei Zhang,
- Fei Zhang,
- Fei Zhang
Affiliations
- He Zhang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- He Zhang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- He Zhang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- He Zhang
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Xingxing Han
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xingxing Han
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Xingxing Han
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xingxing Han
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Zhaosong Wang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Zhaosong Wang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Zhaosong Wang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Zhaosong Wang
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Zhiyong Wang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Zhiyong Wang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Zhiyong Wang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Zhiyong Wang
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Yanfen Cui
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Yanfen Cui
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Yanfen Cui
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Yanfen Cui
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Ran Tian
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ran Tian
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Ran Tian
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Ran Tian
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Yuying Zhu
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Yuying Zhu
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Yuying Zhu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Yuying Zhu
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Baoai Han
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Baoai Han
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Baoai Han
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Baoai Han
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Hui Liu
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Hui Liu
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Hui Liu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Hui Liu
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Xiaoyan Zuo
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Xiaoyan Zuo
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Xiaoyan Zuo
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Xiaoyan Zuo
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Sixin Ren
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Sixin Ren
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Sixin Ren
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Sixin Ren
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Jianfei Tian
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Jianfei Tian
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Jianfei Tian
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Jianfei Tian
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Ruifang Niu
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Ruifang Niu
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Ruifang Niu
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Ruifang Niu
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- Fei Zhang
- Public Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Fei Zhang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
- Fei Zhang
- Tianjin’s Clinical Research Center for Cancer, Tianjin, China
- Fei Zhang
- Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China
- DOI
- https://doi.org/10.3389/fcell.2021.719209
- Journal volume & issue
-
Vol. 9
Abstract
ATP-binding cassette (ABC) transporter family are major contributors to the drug resistance establishment of breast cancer cells. Breast cancer resistant protein (BCRP), one of the ABC transporters, has long been recognized as a pump that effluxes the therapeutic drugs against the concentration gradient. However, recent studies suggest that the biological function of BCRP is not limited in its drug pump activity. Herein, the role of BCRP in the proliferation and survival of drug-resistant breast cancer cells was investigated. We found that BCRP is not the major drug pump to efflux epirubicin in the resistant cells that express multiple ABC transporters. Silencing of BCRP significantly impairs cell proliferation and induces apoptosis of the resistant cells in vitro and in vivo. RNA-sequencing and high-throughput proteomics suggest that BCRP is an inhibitory factor of oxidative phosphorylation (OXPHOS). Further research suggests that BCRP is localized in the mitochondria of the resistant cells. Knockdown of BCRP elevated the intracellular reactive oxygen species level and eventually promotes the cell to undergo apoptosis. This study demonstrated that BCRP exerts important onco-promoting functions in the drug-resistant breast cancer cells independent of its well-recognized drug efflux activity, which shed new light on understanding the complex functional role of ABC transporters in drug-resistant cells.
Keywords
- drug-resistant breast cancer
- breast cancer resistant protein
- reactive oxygen species
- survival
- proliferation